Stockscreener 앱 받기
0.841
13.83%
-0.135
시간 외 거래:
.88
0.039
+4.64%
전일 마감가:
$0.976
열려 있는:
$0.9986
하루 거래량:
427.47K
Relative Volume:
3.11
시가총액:
$19.91M
수익:
-
순이익/손실:
$-22.29M
주가수익비율:
-0.576
EPS:
-1.46
순현금흐름:
$-17.12M
1주 성능:
-22.13%
1개월 성능:
-45.03%
6개월 성능:
-43.56%
1년 성능:
-51.67%
1일 변동 폭
$0.8101
$1.02
1주일 범위
$0.8101
$1.11
52주 변동 폭
$0.8101
$4.59
엔라이벡스 Stock (ENLV) Company Profile
ENLV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ENLV | 0.841 | 19.91M | 0 | -22.29M | -17.12M | -1.46 |
| VRTX | 450.37 | 115.10B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.07B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.20B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 25.09B | 3.30B | -501.07M | 1.03B | 11.54 |
엔라이벡스 Stock (ENLV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-02 | 재확인 | H.C. Wainwright | Buy |
엔라이벡스 주식(ENLV)의 최신 뉴스
Enlivex Therapeutics to Invest in Bitcoin as Part of Cash Management Strategy - Binance
Enlivex Therapeutics : X Adopts Bitcoin Treasury Reserve Strateg - Marketscreener.com
Enlivex Adopts Bitcoin Treasury Reserve Strategy - GlobeNewswire
Enlivex Therapeutics to Buy Up to $1M in Bitcoin as Treasury Reserve Asset | ENLV Stock News - StockTitan
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Significant Growth in Short Interest - Defense World
Armistice Capital, LLC Expands Stake in Enlivex Therapeutics Ltd - GuruFocus.com
Enlivex Announces the Dosing of the First Patient in a - GlobeNewswire
Enlivex Launches Phase I Trial for Novel Psoriatic Arthritis Treatment Allocetra™ | ENLV Stock News - StockTitan
Enlivex stock hits 52-week low at $1.15 amid market challenges - Investing.com Canada
Enlivex Announces the Enrollment and Dosing of the First 10 - GlobeNewswire
Enlivex's Allocetra Advances: Phase II Trial Launches for Knee Osteoarthritis Treatment | ENLV Stock News - StockTitan
Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should Know - MSN
Enlivex Therapeutics Reschedules Annual Shareholders Meeting - TipRanks
Enlivex Receives Notice of Allowance for Japanese Patent - GlobeNewswire
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis - StockTitan
New Strong Buy Stocks for October 23rd - MSN
New Strong Buy Stocks For October 23rd - Barchart
Enlivex stock moves forward as Danish agency approves Phase 2 for knee OA By Investing.com - Investing.com South Africa
Enlivex stock moves forward as Danish agency approves Phase 2 for knee OA - Investing.com Australia
EF Hutton maintains price target on Enlivex after trial advancement By Investing.com - Investing.com Australia
Enlivex Advances Knee Osteoarthritis Treatment Trial - TipRanks
Enlivex Receives Authorization from the Danish Medicines - GlobeNewswire
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis - StockTitan
ENLVEnlivex Therapeutics Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Enlivex Progresses to Phase II for Knee Arthritis Treatment - TipRanks
Enlivex Announces Positive DSMB Recommendation to Initiate - GlobeNewswire
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis - StockTitan
India News | ⚡Kolkata-Based Company Ellenbarrie Industrial Gases Files IPO Papers - LatestLY
Enliven Therapeutics director sells $28,458 in company stock By Investing.com - Investing.com Canada
Enliven Therapeutics Announces Details Regarding the - GlobeNewswire
Ellenbarrie Industrial Gases Files For IPO To Raise Rs 400 Crore - NDTV Profit
Enmy & The Cure - RAMzine
ENLV’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation - Simply Wall St
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy - MSN
Enlivex Announces 2024 Shareholder Meeting - TipRanks
Enlivex Therapeutics (NASDAQ:ENLV) Given Buy Rating at HC Wainwright - Defense World
Enlivex stock poised for growth with key trial readouts by 2025, says H.C. Wainwright - Investing.com India
Enlivex Therapeutics Financials Indicate Net Loss - TipRanks
Enlivex Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV - StockTitan
Enlivex shares rise on EF Hutton's Buy rating By Investing.com - Investing.com Australia
Enlivex shares rise on EF Hutton's Buy rating - Investing.com India
Enlivex Therapeutics (NASDAQ:ENLV) Trading Up 1.9% - Defense World
Enlivex Advances Psoriatic Arthritis Treatment with Allocetra™ - TipRanks
Enlivex Receives Regulatory Authorization For The - GlobeNewswire
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis - StockTitan
Enlivex Therapeutics and Biotricity Interviews to Air on the Red - WICZ
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent - openPR
엔라이벡스 (ENLV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
3.55%
자본화:
|
볼륨(24시간):